Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

50
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
50
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.5K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.5K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

52
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
52

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy.

Circulation. Heart failure·2019
Same author

Tropomyosin pseudo-phosphorylation results in dilated cardiomyopathy.

The Journal of biological chemistry·2018
Same author

Early sensitization of myofilaments to Ca2+ prevents genetically linked dilated cardiomyopathy in mice.

Cardiovascular research·2017
Same author

N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy.

American journal of physiology. Heart and circulatory physiology·2015
Same author

Cardiac myosin light chain phosphorylation and inotropic effects of a biased ligand, TRV120023, in a dilated cardiomyopathy model.

Cardiovascular research·2015
Same author

Ceramide-mediated depression in cardiomyocyte contractility through PKC activation and modulation of myofilament protein phosphorylation.

Basic research in cardiology·2014

関連する実験動画

Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K

拡張 心筋 病 - 根本 的 な 原因 を 調べる

David F Wieczorek1

  • 1Department of Molecular and Cellular Biosciences, University of Cincinnati College of Medicine, 231 Albert Sabin Way.

Medical research archives
|September 2, 2025
PubMed
まとめ
この要約は機械生成です。

拡張性心筋病は 遺伝的および非遺伝的要因に起因する心臓疾患です マウスモデルを用いた研究は この一般的な心臓病の効果を理解し 新しい治療法を開発するのに役立ちます

さらに関連する動画

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K

関連する実験動画

Last Updated: Sep 9, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.8K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.9K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.7K

科学分野:

  • 心臓病科
  • 遺伝学
  • 分子生物学

背景:

  • 心血管疾患は死亡の主な原因で,拡張性心筋病は10万人に5~8人に及ぶ.
  • 拡張性心筋病は,心室の膨張,シストリック機能の低下,心不全によって特徴付けられます.
  • 拡張性心筋病の原因を理解することは 効果的な治療法の開発に不可欠です

研究 の 目的:

  • 拡張性心筋病の非遺伝的および遺伝的原因をレビューする.
  • 拡張性心筋病のマウスモデルでヒトの変異を調べるため
  • これらの変異の形態学的および生理学的結果を定義する.

主な方法:

  • 非遺伝的病因のレビュー:ウイルス,心臓毒性,レクリエーション用薬物,化学療法.
  • 遺伝的病因に注目する. 細胞骨格とサルコメリックタンパク質の遺伝子.
  • 人間に関連する変異を持つマウスモデルの分析.

主要な成果:

  • 遺伝的でない原因は 感染症,毒素,特定の薬剤です.
  • 遺伝的原因は 細胞骨格とサルコメリックタンパク質をコードする遺伝子の変異を含む.
  • マウスモデルでは 病気のメカニズムや 特定の変異の影響を明らかにしています

結論:

  • マウスモデルでは,拡張性心筋病の病原性について貴重な洞察が得られます.
  • 病気のメカニズムを理解することは 新しい治療戦略の開発の鍵です
  • 拡張性心筋病の予防と治療を改善することを目指しています.